08:40 EDT Scholar Rock (SRRK) up 12% at $48.27 after resubmitting BLA to FDA for apitegromab
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock resubmits BLA to FDA for apitegromab
- Scholar Rock extends rally after Cantor note, shares up 14% to $45.34
- Cantor sees Scholar Rock dominating SMA market after Genentech news
- Cantor sees Scholar Rock dominating SMA market after Genentech drops out
- Scholar Rock jumps 8% after Cantor says Genentech stopped SMA drug